Expert Point of View: U.S. Perspective

Get Permission

2.16.9_rugo.jpg“This is an exciting drug,” said Hope Rugo, MD, Professor of Medicine at University of California, San Francisco. “It is highly effective and extremely well tolerated, with no hair loss, which is very important to patients. It also enables using a lower dose of trastuzumab.”

Dr. Rugo cited these outstanding questions: What is the efficacy of T-DM1 in trastuzumab-resistant patient? What is the toxicity after therapy is stopped? In the study reported at the 2011 European Multidisciplinary Cancer Congress, patients were treated until disease progression. She said T-DM1 will probably be studied in the adjuvant and neoadjuvant setting. “We have to wait for results of EMILIA to validate this phase II study,” she commented. ■

Disclosure: Dr. Rugo has received research funding from Genentech.

Related Articles

T-DM1: Antibody Drug Conjugate Outperforms Standard Anti‑HER2 Therapy in Metastatic HER2-positive Breast Cancer

The investigational antibody-drug conjugate T-DM1 improved progression-free survival over standard chemotherapy with docetaxel plus trastuzumab (Herceptin) when given as first-line treatment of HER2-positive metastatic breast cancer, according to an open-label phase II study reported at the 2011...

Expert Point of View: European Perspective

2.16.9_piccart.jpgMartine Piccart, MD, of the Institut Jules Bordet, Brussels, Belgium, and President-Elect of the European Society for Medical Oncology, was highly enthusiastic about the findings of the phase II T-DM1 study, but said, “We have to remember this is an open-label trial, and in a study like this,...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.